Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, Aug 1996, 1817-1824, Vol 40, No. 8
J Sutcliffe, A Tait-Kamradt and L Wondrack
Macrolide-resistant Streptococcus pyogenes isolates from Finland,
Australia, and the United Kingdom and, more recently, Streptococcus
pneumoniae and S. pyogenes strains from the United States were shown to
have an unusual resistance pattern to macrolides, lincosamides, and
streptogramin B antibiotics. This pattern, referred to as M resistance,
consists of susceptibility to clindamycin and streptogramin B antibiotics
but resistance to 14- and 15-membered macrolides. An evaluation of the
macrolide-lincosamide-streptogramin B resistance phenotypes among our
streptococcal strains collected from 1993 to 1995 suggested that this
unusual resistance pattern is not rare. Eighty-five percent (n = 66) of the
S. pneumoniae and 75% (n = 28) of the S. pyogenes strains in our collection
had an M phenotype. The mechanism of M resistance was not mediated by
target modification, as isolated ribosomes from a pneumococcal strain
bearing the M phenotype were fully sensitive to erythromycin. Further, the
presence of an erm methylase was excluded with primers specific for an erm
consensus sequence. However, results of studies that determined the uptake
and incorporation of radiolabeled erythromycin into cells were consistent
with the presence of a macrolide efflux determinant. The putative efflux
determinant in streptococci seems to be distinct from the multicomponent
macrolide efflux system in coagulase-negative staphylococci. The
recognition of the prevalence of the M phenotype in streptococci has
implications for sensitivity testing and may have an impact on the choice
of antibiotic therapy in clinical practice.
Copyright © 1996 by the American Society for Microbiology. All rights reserved.
Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system
Department of Infectious Diseases, Pfizer, Inc., Groton, Connecticut 06340, USA.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |